The market is punishing Piramal Pharma. Is it…

[ad_1] Already weighed down by global policy uncertainty, the Piramal Pharma counter has extended its correction after its earnings for the fourth quarter of 2024-25 disappointed investors. But is the correction an opportunity for investors…